Elan, Biogen Tumble
Elan Corp. (ELN ) and Biogen Idec (BIIB ) announced the voluntary suspension in the marketing of Tysabri, a treatment for multiple sclerosis. The decision is based on recent reports of two serious adverse events; one fatal and one suspected case of PML.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.